 34item 7managements discussion and analysis of financial condition and results of operations 35item 7aquantitative and qualitative disclosures about market risk 57item 8financial statements and supplementary data 59item 9changes in and disagreements with accountants on accounting and financial disclosure 117item 9acontrols and procedures 117item 9bother information 117   part iii  118item 10directors executive officers and corporate governance 118item 11executive compensation 118item 12security ownership of certain beneficial owners and management and related stockholder matters 118item 13certain relationships and related transactions and director independence 118item 14principal accountant fees and services 118   part iv  118item 15exhibits and financial statement schedules 119   signatures 127   2part iitem 1 businessthe companyboston scientific corporation is a worldwide developer manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties our mission is to transform lives through innovative medical solutions that improve the health of patients around the world when used in this report the terms we us our and the company mean boston scientific corporation and its divisions and subsidiariesour history began in the late 1960s when our cofounder john abele acquired an equity interest in meditech inc a research and development company focused on developing alternatives to surgery in 1969 meditech introduced a family of steerable catheters used in some of the first lessinvasive procedures performed in 1979 john abele joined with pete nicholas to form boston scientific corporation which indirectly acquired meditech this acquisition began a period of active and focused new product development innovation market development and organizational growth since then we have advanced the practice of lessinvasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the bodyour net sales have increased substantially since our formation our growth has been fueled in part by strategic acquisitions designed to improve our ability to take advantage of growth opportunities in the medical device industry our strategic acquisitions have helped us to add promising new technologies to our pipeline and to offer one of the broadest product portfolios in the world for use in lessinvasive procedures we believe that the depth and breadth of our product portfolio has also enabled us to compete more effectively in the current healthcare environment that seeks to improve outcomes and lower costs our category leadership also enables us to compete in a changing contracting landscape and position our products with managed care large buying groups governments and consolidation among hospitals while also expanding internationally and managing the complexities of the global healthcare marketbusiness strategy the following are our five strategic imperativesstrengthen execution to grow sharewe believe that our success is driven by our ability to consistently deliver initiatives that grow profitability and market share we focus on improving the speed and performance of our business units by adding new capabilities processes and innovative technologiesexpand into high growth adjacencieswe seek to diversify our product portfolio by aligning our research and development spend and our business development investment toward higher growth markets and business opportunities we focus on executing on our committed growth adjacencies while increasing our access to developing technologies and solutions through this diversification we expect to increase our opportunity for growth in areas that complement our core businesses drive global expansionby expanding our global commercial presence we seek to increase revenue and market share and strengthen our relationships with leading physicians and their clinical research programs we focus on expanding our presence and existing capabilities in emerging markets and building new capabilities and innovative commercial models in countries whose economies and healthcare sectors are growing rapidly fund the journey to fuel growthwe are driving continuous improvement and cost reduction initiatives to expand our profitability and we are reallocating spending to support our growth initiatives  3develop key capabilitieswe are developing key capabilities that address the needs of the marketplace we are globally focused on building a culture of innovation collaboration caring and high performance while enhancing diversitywe believe that our execution of these strategic imperatives will drive innovation accelerate profitable revenue growth and increase stockholder valueproductsduring 2015 our products were offered for sale by seven core businesses  interventional cardiology cardiac rhythm management crm endoscopy peripheral interventions pi urology and pelvic health neuromodulation and electrophysiology ep in august 2015 we completed the acquisition of the american medical systems male urology portfolio ams portfolio acquisition which includes the mens health and prostate health businesses from endo international plc the ams male urology portfolio is being integrated with our formerly named urology and womens health business and the joint businesses have become urology and pelvic health in addition we entered into certain supply and distribution agreements with stryker corporation stryker in connection with our sale of our neurovascular business in 2011 we substantially completed these agreements in 2013during 2015 we derived 27 percent of our sales from our interventional cardiology business 24 percent of our sales from our crm business 18 percent of our sales from our endoscopy business 12 percent of our sales from our pi business nine percent of our sales from our urology and pelvic health business seven percent of our sales from our neuromodulation business and three percent of our sales from our ep businessthe following section describes certain of our product offerings in addition see 